Leadership change in Corcept's endocrinology division
Corcept named Justin Gunn president of its Endocrinology division, effective Oct. 1, succeeding retiring Sean Maduck.
Gunn will join the executive team, reporting to CEO Joseph K. Belanoff.
Maduck will stay on as a senior commercial advisor.
Gunn joined Corcept in July 2024 as VP of Sales and Commercial Learning in Oncology.
He previously spent nearly 18 years at Gilead, leading sales teams across cardiovascular, respiratory, oncology and virology; earlier roles at Merck and Sepracor.
CORT•
